The temptation to use uncontrolled, early, small studies to support further development of products may prove problematic for emerging biopharma companies.
Phillip Ward
Advertisement
Phillip Ward is the European editor of Applied Clinical Trails.
Articles by Phillip Ward
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Significant differences exist in the characteristics of the priority review drugs approved by the FDA and the European Medicines Agency.
Advertisement
Latest Updated Articles
- Harmonization Can Improve Priority Reviews, Finds New Study
Published: May 29th 2015 | Updated:
- Synexus Pushes Ahead with Central & Eastern Europe Expansion
Published: July 13th 2015 | Updated:
- Small Biopharm Firms Struggle to Meet Development Challenges
Published: February 2nd 2017 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
